Stroke, a leading cause of disability in the aging population, increases the risk for diabetes, subsequent stroke recurrence, and cardiovascular disease complications. The downsizing of private and federal health care resources, along with the anticipated increase in stroke rates as our population ages, mandate that alternative strategies be developed to reduce the public health burden of stroke. This pilot study may facilitate our knowledge of the timing of paretic leg muscle atrophy, fiber type shift, and the progression of worsening of glucose tolerance after stroke. Knowledge of the skeletal muscle changes occurring in the sub-acute stroke period is essential to create new guidelines incorporating exercise rehabilitation, much like cardiac rehabilitation, in order to facilitate and improve the health care of veteran stroke survivors.
The vast majority of cerebrovascular accidents are reported in persons older than 55 years of age and occur in over 780,000 persons each year in the U.S. As our adult population ages, the number of strokes in the United States is anticipated to double, reaching nearly 1.5 million annually by the year 2050. Following stroke, patients remain at continued high risk for recurrent stroke with almost a third of them suffering recurrent stroke within 5 years, even despite optimal medical management. Age and cardiac disease are among the most important longitudinal predictors of cardiovascular health outcomes and survival after stroke. Notably, 75% of chronic stroke survivors have residual disability emphasizing the need for rehabilitation strategies.
Knowledge of the skeletal muscle changes that occur in the early phases after stroke is essential to create new guidelines which incorporate exercise rehabilitation, much like cardiac rehabilitation, in order to facilitate and improve the health care of stroke survivors.
- No intervention Behavioral
Intervention Desc: longitudinal follow-up after stroke ARM 1: Kind: Experimental Label: Acute Stroke Recovery
- Perspective: Prospective
- Sampling: Non-Probability Sample
|Type||Measure||Time Frame||Safety Issue|
|Primary||Change in body composition||baseline, 2 month, 4 month, 6 month||No|
|Primary||Change in Oral Glucose Tolerance||baseline, 2 month, 4 month, 6 month||No|
|Primary||Change in Muscle phenotype||baseline, 2 month, 4 month, 6 month||No|
|Primary||Change in physical function||baseline, 2 month, 4 month, 6 month||No|
|Secondary||Change in biomarkers||baseline, 2 month, 4 month, 6 month||No|
|Secondary||Change in scores of questionnaires||baseline, 2 month, 4 month, 6 month||No|
|Secondary||Change in glucose||change in glucose from baseline to 3 months|
Biospecimen Retention:Samples Without DNA - Blood samples will be analyzed for metabolic biomarkers. Muscle tissue is collected for measurements of muscle phenotype. A urine pregnancy test is performed in women of child bearing age before CT imaging to exclude pregnant women due to the risk to an unborn fetus.